Park Medi IPO

Reviewing Park Medi World Ltd's IPO, one observes a multi-specialty hospital chain, largely owned—a clear positive for long-term stability. The ₹7,000 crore valuation and ₹920 crore fund-raise include fresh funds for debt repayment and expansion. A key concern, however, is the significant allocation for "unidentified inorganic acquisitions." While promoter stake remains high, implying future dilution, the subsidiary structure appears sensible. Critically, the company faces alarming staff attrition, with half its doctors leaving annually. Ethical questions also surface regarding the heavy reliance on in-hospital revenue, hinting at aggressive billing, particularly with government-backed schemes. Financially, robust revenue growth is projected towards ₹1,600-1,700 crore this year, with net profit around ₹280-300 crore after debt reduction. Valuation (P/E low 20s, P/B 3.5-3.7) seems attractive against listed peers. For investors, the attractive valuation suggests potential for both listing gains and long-term returns, buoyed by solid financials and debt reduction plans. However, the alarming staff attrition and ethical concerns regarding revenue generation are significant qualitative risks. While financially compelling, these crucial red flags demand serious consideration. Always perform thorough personal due diligence before investing.